This publication provides guidance to national advocates and civil society organizations in conducting effective advocacy for the successful uptake of misoprostol for prevention and treatment of postpartum hemorrhage (PPH).
Postpartum hemorrhage (PPH)—excessive bleeding after childbirth—is the leading cause of maternal death and injury worldwide. Globally, more than a quarter of maternal deaths are attributed to PPH, with the majority occurring in sub-Saharan Africa. Yet, PPH can be prevented and treated safely and effectively when it does occur, in virtually all settings. Misoprostol is safe, effective, and inexpensive. For the millions of women giving birth at home or in health facilities without reliable electricity, refrigeration, IV therapy, and/or qualified health providers settings where administering oxytocin is not feasible—misoprostol may be the best option for preventing and treating PPH. Multi-country research studies, operations research, and pilot programs have clearly demonstrated that misoprostol can be effectively used in all settings.
Through case studies and an Advocacy for Access Framework, this publication provides concrete examples to support misoprostol’s availability and use at the national level.
English: Advocacy, Approval, Access: Misoprostol for Postpartum Hemorrhage A Guide for Effective Advocacy (5.9 MB)
Français: Plaidoyer, approbation, accés : le misoprostol pour l'Hémorragie du post-partum Guide pour un plaidoyer efficace (2.3 MB)
This publication is only available for download at this time.